Core Viewpoint - The Hong Kong stock market opened slightly lower on August 6, with innovative pharmaceuticals continuing to be active, particularly the high-profile Hong Kong Stock Connect innovative drug ETF (520880), which rose by 1.37% in early trading, aiming for a third consecutive daily gain [1]. Company Highlights - Crystal Tech Holdings (晶泰控股) announced a pipeline collaboration agreement with DoveTree, with a total order scale of approximately HKD 470 billion (USD 59.9 billion), marking one of the largest business development transactions in China's AI pharmaceutical sector by 2025 [2][3]. - Crystal Tech has received an initial payment of USD 51 million under the final agreement and is entitled to further payments of USD 49 million (to be paid within 180 days), as well as potential milestone payments of up to USD 5.89 billion based on regulatory and commercial achievements, along with royalties based on annual net sales [3]. Industry Trends - The National Medical Products Administration reported that 43 innovative drugs were approved in the first half of the year, a 59% year-on-year increase, nearing the total of 48 for the entire year of 2024 [3]. - According to China International Capital Corporation (中金公司), the long-term development trend of the innovative pharmaceutical industry is promising, supported by domestic engineering talent, abundant clinical resources, and favorable policies [3]. - The innovative drug sector is transitioning from a follower to a leader in innovation, with domestic products expected to significantly participate in the global market over the next decade [3]. Market Performance - The Hang Seng Stock Connect Innovative Drug ETF (520880) is the first ETF to passively track the Hang Seng Stock Connect Innovative Drug Select Index, focusing on the innovative drug industry chain with a high concentration of leading stocks [5]. - As of July 31, the Hang Seng Stock Connect Innovative Drug Select Index has risen by 101.58% year-to-date, outperforming the Hang Seng Index (23.50%) and the Hang Seng Technology Index (22.05%) by 78.08 and 79.53 percentage points, respectively [6].

Group 1 - The core viewpoint is that the Hong Kong innovative drug sector is experiencing significant growth, with the Hong Kong Innovative Drug Selected ETF seeing a rise of 1.2% and notable increases in individual stocks such as Jingtai Holdings and Lepu Biopharma [1] - The Hong Kong Innovative Drug Selected ETF (520690) has attracted substantial capital since its listing on August 1, with a net inflow of 29.54 million yuan over the past three trading days, bringing its total size to 359 million yuan [1] - The ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index, focusing on leading innovative drug companies listed in Hong Kong, including companies like BeiGene, Innovent Biologics, WuXi Biologics, and others [1] Group 2 - The innovative drug sector is expected to remain a core focus within the pharmaceutical industry, with sustained optimism regarding its growth and internationalization [2] - The industry is anticipated to benefit from ongoing policy support, enhancing global competitiveness and commercial profitability [2] - The upcoming adjustments in medical insurance catalogs and the promotion of commercial insurance policies are seen as important catalysts for the innovative drug sector in the second half of the year [1]

隔夜美股三大指数集体收跌，中概指数跌0.56%。连续2日反弹的港股三大指数低开，恒指跌0.15%，国 指跌0.21%，恒生科技指数跌0.31%。盘面上，大型科技股多数呈现下跌行情，其中，百度跌超1%，阿 里巴巴、小米、美团、网易均飘绿，腾讯、京东小幅上涨；创新药概念股继续走强，与DoveTree完成总 订单规模约470亿港元的管线合作签约，晶泰科技大涨15%，歌礼制药、康方生物、远大医药、金斯瑞 生物科技皆上涨；宇树发布新款四足机器狗，机器人概念股多数活跃，纸业股继续昨日上涨。另一方 面，餐饮股走低，百胜中国跌超6%，钢铁股、汽车股、电信股、快递物流股普遍下跌。(格隆汇) 相关事件 港股收评：恒生指数涨0.62%！光伏、钢铁成亮点，军工、芯片股表现疲软 港股收评：恒生指数跌 0.56%！内房股、汽车股低迷，黄金股逆势爆发 港股收评：三大指数涨跌不一，恒生科技指数涨 0.56%，医药、军工、汽车大涨 港股收评：恒指再度失守24000，恒生科技指数跌0.33%，医药、芯片、 券商大涨居前 ...

【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com (责任编辑：宋政 HN002) 格隆汇8月6日｜隔夜美股三大指数集体收跌，中概指数跌0.56%。连续2日反弹的港股三大指数低开， 恒指跌0.15%，国指跌0.21%，恒生科技指数跌0.31%。盘面上，大型科技股多数呈现下跌行情，其中， 百度跌超1%，阿里巴巴、小米、美团、网易均飘绿，腾讯、京东小幅上涨；创新药概念股继续走强， 与DoveTree完成总订单规模约470亿港元的管线合作签约，晶泰科技大涨15%，歌礼制药、康方生物、 远大医药、金斯瑞生物科技皆上涨；宇树发布新款四足机器狗，机器人概念股多数活跃，纸业股继续昨 日上涨。另一方面，餐饮股走低，百胜中国跌超6%，钢铁股、汽车股、电信股、快递物流股普遍下 跌。(格隆汇) ...

Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (00728) at 74.86%, Green Power Environmental (01330) at 70.22%, and China Shenhua (01088) at 67.10% [1] - The largest increases in holding amounts over the last five trading days were seen in the following companies: Yingfu Fund (02800) with +5.886 billion, Hang Seng China Enterprises (02828) with +4.157 billion, and Li Auto-W (02015) with +2.947 billion [2] - The largest decreases in holding amounts over the last five trading days were recorded for Kangfang Biopharmaceutical (09926) with -0.774 billion, HSBC Holdings (00005) with -0.523 billion, and China Hongqiao (01378) with -0.506 billion [3] Group 1: Top Holding Ratios - China Telecom (00728) holds 10.39 billion shares, representing 74.86% of its total [1] - Green Power Environmental (01330) holds 0.284 billion shares, representing 70.22% of its total [1] - China Shenhua (01088) holds 2.266 billion shares, representing 67.10% of its total [1] Group 2: Recent Increases in Holdings - Yingfu Fund (02800) saw an increase of +5.886 billion in holding amount, with a change of +23.21079 million shares [2] - Hang Seng China Enterprises (02828) increased by +4.157 billion, with a change of +4.54198 million shares [2] - Li Auto-W (02015) increased by +2.947 billion, with a change of +2.86721 million shares [2] Group 3: Recent Decreases in Holdings - Kangfang Biopharmaceutical (09926) experienced a decrease of -0.774 billion, with a change of -0.47511 million shares [3] - HSBC Holdings (00005) saw a decrease of -0.523 billion, with a change of -0.54260 million shares [3] - China Hongqiao (01378) decreased by -0.506 billion, with a change of -2.37590 million shares [3]

Core Insights - The majority of ordinary stock funds in China have performed well in the first seven months of the year, with 92% of the 983 funds showing positive returns [1] - The top-performing fund, Huaan Medical Biotechnology, achieved a remarkable increase of over 105% [1] - The strong performance of these funds is largely attributed to their heavy investments in the pharmaceutical sector, with several stocks experiencing significant gains [2][3] Fund Performance - Huaan Medical Biotechnology Fund A and C led the performance with increases of 105.40% and 104.88% respectively, heavily investing in companies like Innovent Biologics and Stone Pharma [1] - Other notable funds include Jiashi Mutual Selection and Fortune Medical Innovation, which saw increases of 97.28% and 96.67% respectively, also focusing on pharmaceutical stocks [2] - Funds with over 80% growth include Ping An Medical Selected Stocks and Penghua Medical Technology Stocks, indicating a strong trend in the healthcare investment space [3] Underperforming Funds - Only seven funds experienced declines exceeding 10%, primarily in sectors like consumer goods, new energy, and technology [4] - The Minsheng Plus Silver Preferred Stock Fund saw a decline of 13.06%, with major holdings in companies like CATL and BYD [4] - Other funds with significant declines include Changxin Consumer Selected Quantitative Stocks and Beixin Ruifeng Preferred Growth, both heavily invested in the liquor sector [5]

Group 1 - In the first seven months of the year, 7656 out of 8237 mixed funds with comparable performance saw an increase in net value, representing 92.95% of the total [1] - Eight mixed funds achieved a growth rate exceeding 100%, primarily focusing on investments in pharmaceutical companies [1] - The top-performing mixed funds include Changcheng Pharmaceutical Industry Select Mixed Fund A and C, with returns of 127.05% and 126.36% respectively [1] Group 2 - The other six mixed funds with growth rates over 100% include Bank of China Hong Kong Stock Connect Pharmaceutical Mixed Fund A, Yongying Pharmaceutical Innovation Select Mixed Fund A and C, and others, with returns ranging from 102.09% to 113.51% [2] - Yongying Pharmaceutical Innovation Select Mixed Fund A and C, established on November 22, 2022, reported returns of 90.60% and 88.63% respectively [2] - The top holdings of Yongying Pharmaceutical Innovation Select Mixed Fund A and C include companies like Innovent Biologics and BeiGene [2] Group 3 - The worst-performing mixed fund in the first seven months was Qianhai Kaiyuan Artificial Intelligence Theme Mixed Fund A, with a return of -19.15% [3] - This fund, established on May 4, 2016, has a cumulative return of 20.46% since inception [3] - The fund's focus in the second quarter was on stocks in the electronics and communication sectors related to edge AI [3]

Group 1 - The article provides a ranking of open-end funds based on their net asset value growth, highlighting the top 10 funds with significant increases [2][4][5] - The top-performing funds include Huatai-PB Hong Kong Stock Connect Medical Selected Mixed Fund A and C, with net values of 1.2442 and 1.2438 respectively, both showing a growth of 0.05 [2][4] - The article mentions that a total of 28,277 funds have updated their net values, indicating a broad market activity [3] Group 2 - The bottom 10 funds in terms of net value growth include Huafu Health and Entertainment Flexible Allocation Mixed Fund A and C, with significant declines [5] - The article notes that the Shanghai Composite Index experienced a rebound, while the ChiNext Index showed a mixed performance, with a trading volume of 1.61 trillion [7] - The leading sectors include communication equipment, which saw a rise of over 2%, while the aviation and software service sectors lagged [7] Group 3 - The article highlights that the top holdings in the funds are primarily in the pharmaceutical sector, with a concentration of 67.67% in the top 10 holdings of the funds [9] - Notable stocks among the top holdings include Innovent Biologics and WuXi Biologics, which experienced significant daily increases [9] - The funds are categorized into passive index funds tracking the Hong Kong Stock Connect Innovation Drug Index and active mixed funds focusing on the pharmaceutical sector [9]

Core Viewpoint - The Hong Kong innovative drug company, Keren Biotechnology, has reached a market capitalization of HKD 101 billion, marking its entry into the exclusive club of companies valued over HKD 100 billion in the innovative drug sector [1][4]. Group 1: Market Performance - As of August 5, Keren Biotechnology's stock closed at HKD 433 per share, reflecting a sevenfold increase from its IPO price in July 2023 [4]. - The innovative drug sector in Hong Kong has seen multiple stocks reaching new highs, with seven companies now having market capitalizations exceeding HKD 100 billion, including Keren Biotechnology, Hengrui Medicine, and Innovent Biologics [1][2]. Group 2: Business Development (BD) and Collaborations - Hengrui Medicine announced a collaboration with GlaxoSmithKline (GSK) on a PDE3/4 inhibitor and up to 11 other projects, indicating a trend of active business development in the sector [2]. - The recent announcement by CSPC Pharmaceutical regarding a licensing agreement with Madrigal for a GLP-1 receptor agonist also highlights the growing BD activities among innovative drug companies [2]. Group 3: Policy and Market Sentiment - Recent policy adjustments, such as the initiation of a commercial health insurance innovative drug directory, are expected to enhance the payment landscape for innovative drugs, contributing to positive market sentiment [2]. - The overall optimistic sentiment in the Hong Kong innovative drug market is driving the continuous rise in stock prices [2]. Group 4: Company-Specific Developments - Keren Biotechnology is evolving into a comprehensive biopharmaceutical platform, with its lead product, sac-TMT, showing significant progress in clinical trials for various cancer treatments [4][5]. - The company has multiple differentiated ADC pipelines and is advancing its HER2 ADC, A166, with two applications currently under review in China [5]. - Keren Biotechnology is expected to reach operational breakeven within two years, reflecting its strategic growth trajectory [5].

Core Viewpoint - Sanofi has decided to cease the promotion of its cholesterol-lowering drug, Polatad (Alirocumab injection), in the Chinese market due to global supply issues and a shift in its cardiovascular market strategy [1][6]. Market Dynamics - The PCSK9 market is becoming increasingly competitive, with more domestic alternatives being included in the National Medical Insurance Drug List, leading to a more diversified market [6][7]. - Polatad's market share has been significantly eroded by competitors, with sales figures showing a rise in sales for rival products like Repatha (from 130 million yuan to 1.323 billion yuan) while Polatad's sales increased from 17 million yuan to 629 million yuan during the same period [7]. Patient Impact - Patients using Polatad have expressed minimal concern regarding its withdrawal, indicating that they can easily switch to alternative medications without significant issues [2][5]. - Clinical experts have noted that the mechanism of action for PCSK9 inhibitors is similar across different products, suggesting that patients can transition between these medications without adverse effects [4][8]. Clinical Alternatives - Multiple alternatives to Polatad are available, including Repatha and domestic products like Xinbile (Torlipressin) and other PCSK9 monoclonal antibodies, which have been approved and are effective in lowering LDL-C levels [6][8]. - The introduction of new therapies, such as Novartis's siRNA drug inclisiran, which offers a more convenient dosing schedule, further enhances the options available for patients [8].